A poster, titled ‘Neuroprotection in CNS demyelinating disease by SIRT1 activators, a potential oral therapy’ presented at the annual meeting of the american neurological association, showed that oral
AstraZeneca has agreed to pay $30 million to acquire NPS’s assets. NPS intends to use the proceeds to support further development of its late-stage product pipeline. Under the
Mixed dyslipidemia is the presence of elevated levels of bad cholesterol, low-density lipoproteins and triglycerides, and low levels of good cholesterol, high-density lipoproteins in the blood. The Phase
The dose-sparing ability could be critical in extending limited vaccine supplies to protect a great number of people in the event of a pandemic influenza outbreak, according to
Through X-ray crystallographic studies, Ariad says its study shows in detail how inhibitors of the Bcr-Abl protein, such as AP24534, are able to overcome the structural changes induced
Amarin believes that its lipid-based technology platform for the targeted transport of molecules through the liver or to the brain can be leveraged in a wide range of
In the safety study, Advaxis reported treatment of 15 patients in three dosage groups with 30 minute 250ml infusions of Lovaxin C at 3-week intervals. Patients were observed
The compound, civamide, a proprietary TRPV-1 receptor modulator and neuronal calcium channel blocker, is in Phase III clinical trials in an intranasal formulation to treat various types of
The companies are pursuing the deal despite opposition from a key Bioenvision shareholder, SCO Capital Partners LLC. The petition seeks that the court permit Bioenvision to reconvene the
This is the second Zealand-developed gap junction modifier, known as ZP1609 (GAP-134), that Wyeth has advanced into clinical trials. ZP1609 has shown pharmacological effects in animal models of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.